Literature DB >> 7095894

Establishment and characterization of a human myeloma cell line (KMM-1).

A Togawa, N Inoue, K Miyamoto, H Hyodo, M Namba.   

Abstract

A new cell line (KMM-1) was established from a subcutaneous plasmacytoma of a 62-year-old male with multiple myeloma. Immunological studies indicated that cultured cells were derived from the same clone of myeloma cells in vivo: smeared cells were stained with fluorescein-conjugated globulin of antisera monospecific to lambda-chain, and lambda-chains in the cell extracts and in culture media were identical to the Bence-Jones protein found in the patient's urine. The cell line grew in suspension with prominent nucleoli and rough endoplasmic reticulum. Cells had the karyotype of 47, X, -Y, Iq+, -2, +t(1:2) (cen:cen), +7, 12q+, 14q+, +mar and carried no Epstein-Barr virus-determined nuclear antigen. Surface markers were as follows; E rosette (-), IgG Fc receptor (-), C3 receptor (-), S-Ig (+), TdT (-), asialo-GM1 (-). The reasons for the successful establishment of the myeloma cell line are discussed.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7095894     DOI: 10.1002/ijc.2910290502

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  11 in total

1.  Human monoclonal antibody. Construction of stable clones reactive with human breast cancer.

Authors:  A J Strelkauskas; C L Taylor
Journal:  Cancer Immunol Immunother       Date:  1986       Impact factor: 6.968

Review 2.  Human monoclonal antibodies.

Authors:  S P Cole; B G Campling; T Atlaw; D Kozbor; J C Roder
Journal:  Mol Cell Biochem       Date:  1984-06       Impact factor: 3.396

3.  Establishment of five human myeloma cell lines.

Authors:  M Namba; T Ohtsuki; M Mori; A Togawa; H Wada; T Sugihara; Y Yawata; T Kimoto
Journal:  In Vitro Cell Dev Biol       Date:  1989-08

Review 4.  Human monoclonal antibodies: methods of production and some aspects of their application in oncology.

Authors:  L Olsson
Journal:  Med Oncol Tumor Pharmacother       Date:  1984

5.  Multiple myeloma cells expressing low levels of CD138 have an immature phenotype and reduced sensitivity to lenalidomide.

Authors:  Yawara Kawano; Shiho Fujiwara; Naoko Wada; Mikiko Izaki; Hiromichi Yuki; Yutaka Okuno; Kenichi Iyama; Hiroshi Yamasaki; Akira Sakai; Hiroaki Mitsuya; Hiroyuki Hata
Journal:  Int J Oncol       Date:  2012-07-04       Impact factor: 5.650

6.  Lactate, a putative survival factor for myeloma cells, is incorporated by myeloma cells through monocarboxylate transporters 1.

Authors:  Shiho Fujiwara; Naoko Wada; Yawara Kawano; Yutaka Okuno; Yoshitaka Kikukawa; Shinya Endo; Nao Nishimura; Nina Ueno; Hiroaki Mitsuya; Hiroyuki Hata
Journal:  Exp Hematol Oncol       Date:  2015-04-21

7.  Shikonin, dually functions as a proteasome inhibitor and a necroptosis inducer in multiple myeloma cells.

Authors:  Naoko Wada; Yawara Kawano; Shiho Fujiwara; Yoshitaka Kikukawa; Yutaka Okuno; Masayoshi Tasaki; Mitsuharu Ueda; Yukio Ando; Kazuya Yoshinaga; Masaki Ri; Shinsuke Iida; Takayuki Nakashima; Yukimasa Shiotsu; Hiroaki Mitsuya; Hiroyuki Hata
Journal:  Int J Oncol       Date:  2014-12-19       Impact factor: 5.650

8.  Potential small guide RNAs for tRNase ZL from human plasma, peripheral blood mononuclear cells, and cultured cell lines.

Authors:  Sho Ninomiya; Mitsuoki Kawano; Takashi Abe; Tatsuya Ishikawa; Masayuki Takahashi; Masato Tamura; Yoshiaki Takahashi; Masayuki Nashimoto
Journal:  PLoS One       Date:  2015-03-02       Impact factor: 3.240

9.  PDK1 inhibition is a novel therapeutic target in multiple myeloma.

Authors:  S Fujiwara; Y Kawano; H Yuki; Y Okuno; K Nosaka; H Mitsuya; H Hata
Journal:  Br J Cancer       Date:  2012-11-29       Impact factor: 7.640

10.  ZFP36L1 negatively regulates plasmacytoid differentiation of BCL1 cells by targeting BLIMP1 mRNA.

Authors:  Asghar Nasir; John D Norton; Maria Baou; Anna Zekavati; Marie-Jose Bijlmakers; Steve Thompson; John J Murphy
Journal:  PLoS One       Date:  2012-12-20       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.